ARCHIVES

FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds

This article is from The Cancer Letter archive.

Vol. 26 No. 12 | December 26, 2003

Download PDF Visit The Full Archive

Related Articles

“What Is Good For NCI Is Good For NIH,” Broder Says In Address

January 13, 1995

Gynecologic Oncology Group To Conduct Phase III Trial of Xyotax For Ovarian Cancer

April 30, 2004

In Brief: Proposed Drug Act Revisions Would Provide Quick Approval Of “Breakthroughs,” IND_NDA Changes

March 24, 1978

Waksal Pleads Guilty To Securities Fraud

October 18, 2002

Study Finds High-Risk Women Reluctant To Take Tamoxifen

December 25, 2009

Eight Scientists Receive $800,000 From Milken

January 12, 1990